Publications by authors named "F Eladoumikdachi"
Bilateral risk-reducing mastectomy (BRRM) is the surgical removal of both breasts to reduce the risk of cancer. In this Society of Surgical Oncology position statement, we review the literature addressing the indications, outcomes, and risks of BRRM to update the society's 2017 statement. We held a virtual meeting to outline key topics and conducted a literature search using PubMed to identify relevant articles.
View Article and Find Full Text PDFFirst Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer.
Int J Radiat Oncol Biol Phys
February 2025
Purpose: A radiation therapy (RT) boost to the tumor bed is an important component of breast-conserving therapy in early breast cancer. This prospective phase 2 study assessed the feasibility of delivering the RT boost before surgery. We hypothesize wound complication rates to be comparable with postoperative RT and the target boost volume to be smaller than standard postoperative RT.
View Article and Find Full Text PDFArticle Synopsis
- - Rates of contralateral mastectomy (CM) for unilateral breast cancer are rising in the U.S., with patients considering factors like the risk of contralateral breast cancer (CBC) and aesthetic concerns, while surgeons focus mainly on CBC risk.
- - Although CM can lower the risk of developing new breast cancer in high-risk patients, it hasn't been shown to improve overall survival rates.
- - Recommendations include performing mammograms within a year before CM but not routine preoperative MRIs or postoperative imaging, and it's advised that shared decision-making can help manage the rates of CM.
Article Synopsis
- The study investigates the long-term outcomes of accelerated partial breast irradiation (APBI) in early-stage breast cancer patients, focusing on daily doses that are equivalent to whole breast radiation.
- Over a 12-year follow-up, a total of 34 patients were treated, with a low recurrence rate of 5.8% and high survival rates of 93.5% for breast recurrence-free and 93.2% overall.
- The findings suggest that this APBI method is well-tolerated, with most patients achieving good to excellent cosmetic results while experiencing minimal long-term side effects.
Background: This study aims to capture clinical and surgical practice patterns of patients with deleterious mutations in partner and localizer of BRCA2 (PALB2), checkpoint kinase 2 (CHEK2) and ataxia telangiesctasia mutated (ATM) genes.
Materials And Methods: This study is a retrospective chart review of patients with PALB2, CHEK2 or ATM mutations. Patient demographics, testing indications, management decisions, and surveillance strategies were recorded.